Patents by Inventor Staffan Eriksson
Staffan Eriksson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11959919Abstract: Method of selecting treatment for a subject diagnosed with cancer comprises contacting antibody that binds specifically to thymidine kinase 1 (TK1) protein with a first body fluid sample before completing cancer treatment; determining a first amount of antibody binding to TK1 protein in the first sample; correlating the first amount to a first concentration of TK1 protein using a standard curve correlating an amount of antibody binding to recombinant human TK1 (rhTK1) and a concentration of rhTK1; contacting the antibody with a second body fluid sample within one to six months after the cancer treatment; determining a second amount of antibody binding to TK1 protein in the second sample; correlating the second amount to a second concentration using the curve; identifying the patient as having a high risk of future cancer relapse if the second concentration is ? the first concentration; and selecting an adjuvant treatment based on the identification.Type: GrantFiled: December 30, 2019Date of Patent: April 16, 2024Assignee: AROCELL ABInventors: Sven Skog, Staffan Eriksson, Bernard Tribukait, Qimin He
-
Publication number: 20240044903Abstract: A kit useful for determination of canine TK1 in a sample is disclosed. The kit comprises a first monoclonal antibody, or a fragment thereof, immobilized to a support or intended to be immobilized to a support. The kit also comprises a second monoclonal antibody, or a fragment thereof. One of the monoclonal antibodies has specificity for a peptide consisting of an amino acid sequence from a C-terminal region of canine TK1 and the other monoclonal antibody has specificity for a peptide consisting of an amino acid sequence from an active site of TK1.Type: ApplicationFiled: June 2, 2023Publication date: February 8, 2024Applicant: Koza Novel Materials Korea Co. Ltd.Inventors: Staffan ERIKSSON, Henrik RÖNNBERG, Kiran Kumar JAGARLAMUDI
-
Publication number: 20230070840Abstract: A method for predicting patient survival comprises determining a level of STK1 (serum thymidine kinase 1) material in a body sample from a patient diagnosed with prostate cancer using an antibody or a fragment thereof specifically binding to a serum form of human TK1. The method also comprises predicting survival of the patient based on the determined level of STK1 material in the body sample.Type: ApplicationFiled: January 29, 2021Publication date: March 9, 2023Inventors: Staffan ERIKSSON, Martin SHAW, Teuvo TAMMELA, Teemu MURTOLA
-
Publication number: 20220221456Abstract: The present invention relates to diagnosing and classifying respiratory infections based on determined TK1 protein levels in body samples. In particular, a respiratory infection can be diagnosed and classified as Mycoplasma pneumonia caused by Mycoplasma pneumoniae based on the determined TK1 protein level.Type: ApplicationFiled: May 5, 2020Publication date: July 14, 2022Inventors: Staffan ERIKSSON, Per VENGE
-
Publication number: 20200124608Abstract: Method of selecting treatment for a subject diagnosed with cancer comprises contacting antibody that binds specifically to thymidine kinase 1 (TK1) protein with a first body fluid sample before completing cancer treatment; determining a first amount of antibody binding to TK1 protein in the first sample; correlating the first amount to a first concentration of TK1 protein using a standard curve correlating an amount of antibody binding to recombinant human TK1 (rhTK1) and a concentration of rhTK1; contacting the antibody with a second body fluid sample within one to six months after the cancer treatment; determining a second amount of antibody binding to TK1 protein in the second sample; correlating the second amount to a second concentration using the curve; identifying the patient as having a high risk of future cancer relapse if the second concentration is ? the first concentration; and selecting an adjuvant treatment based on the identification.Type: ApplicationFiled: December 30, 2019Publication date: April 23, 2020Inventors: Sven SKOG, Staffan ERIKSSON, Bernard TRIBUKAIT, Qimin HE
-
Patent number: 10551385Abstract: Method of determining a likelihood of cancer relapse in a subject who has completed cancer tumor surgery, radiotherapy treatment and/or chemotherapy treatment comprises contacting an antibody that binds specifically to a serum form of thymidine kinase 1 (STK1) protein with a blood serum sample one to six months after completing the surgery and/or treatment, and before any cancer relapse has been detected; determining an amount of antibody binding to STK1 protein in the sample; correlating the amount of antibody binding to STK1 protein to a concentration of STK1 protein in the sample; and based on the concentration of STK1 protein in the sample, generating decision support information representative of a likelihood of cancer relapse in the subject one to ten years after completion of the surgery and/or treatment, the decision support information comprising a likelihood value defining one of a high or low likelihood of cancer relapse.Type: GrantFiled: November 21, 2016Date of Patent: February 4, 2020Assignee: AROCELL ABInventors: Sven Skog, Staffan Eriksson, Bernard Tribukait, Qimin He
-
Publication number: 20190185582Abstract: A kit useful for determination of non-human mammal TK1 in a sample is disclosed. The kit comprises a first antibody immobilized to a support or intended to be immobilized to a support. The kit also comprises a second antibody. One of the antibodies has specificity for a peptide consisting of a first amino acid sequence from a C-terminal region of non-human mammal TK1 and the other antibody has specificity for a peptide consisting of an amino acid sequence from an active site of TK1 or for a peptide consisting of a second amino acid sequence from the C-terminal region.Type: ApplicationFiled: August 9, 2017Publication date: June 20, 2019Applicant: Alertix Veterinary Diagnostics ABInventors: Staffan ERIKSSON, Henrik RÖNNBERG, Kiran Kumar JAGARLAMUDI
-
Publication number: 20190002587Abstract: The embodiments relate to monoclonal antibodies or fragments capable of binding to a serum form of human TK1 and to kits and methods involving the use of such monoclonal antibodies or fragments.Type: ApplicationFiled: September 14, 2018Publication date: January 3, 2019Inventor: Staffan ERIKSSON
-
Patent number: 10100128Abstract: Monoclonal antibodies and fragments thereof are capable of binding to a serum form of human TK1. Kits and methods involve the use of such monoclonal antibodies or fragments.Type: GrantFiled: December 18, 2014Date of Patent: October 16, 2018Assignee: AROCELL ABInventor: Staffan Eriksson
-
Publication number: 20170067900Abstract: Method of determining a likelihood of cancer relapse in a subject who has completed cancer tumor surgery, radiotherapy treatment and/or chemotherapy treatment comprises contacting an antibody that binds specifically to a serum form of thymidine kinase 1 (STK1) protein with a blood serum sample one to six months after completing the surgery and/or treatment, and before any cancer relapse has been detected; determining an amount of antibody binding to STK1 protein in the sample; correlating the amount of antibody binding to STK1 protein to a concentration of STK1 protein in the sample; and based on the concentration of STK1 protein in the sample, generating decision support information representative of a likelihood of cancer relapse in the subject one to ten years after completion of the surgery and/or treatment, the decision support information comprising a likelihood value defining one of a high or low likelihood of cancer relapse.Type: ApplicationFiled: November 21, 2016Publication date: March 9, 2017Inventors: Sven SKOG, Staffan ERIKSSON, Bernard TRIBUKAIT, Qimin HE
-
Publication number: 20160311927Abstract: The embodiments relate to monoclonal antibodies or fragments capable of binding to a serum form of human TK1 and to kits and methods involving the use of such monoclonal antibodies or fragments.Type: ApplicationFiled: December 18, 2014Publication date: October 27, 2016Applicant: AROCELL ABInventor: Staffan Eriksson
-
Patent number: 9069091Abstract: A technique includes generating one or more sweep sequences for one or more seismic vibrators for a seismic survey and evaluating a cost for the sequence(s). The technique includes perturbing the sequence(s) and continuing the evaluation and perturbing until the cost is within a limit or a maximum number of perturbations is reached.Type: GrantFiled: July 16, 2008Date of Patent: June 30, 2015Assignee: WESTERNGECO L.L.C.Inventors: Kambiz Iranpour, Staffan Eriksson, Christer Hoerlin
-
Publication number: 20150034165Abstract: A fluidic modulator having a body forming a flow aperture between an inlet and an outlet, the flow aperture having a nominal diameter less than the inlet diameter and the outlet diameter whereby the flow aperture provides a constriction to a fluid flowing axially from the inlet to the outlet, and a moveable portion operable to alter the flow aperture. To create a modulated pressure pulse the moveable portion may be for example radially shifted in the flow aperture, rotated in the flow aperture, or the rotation of the moveable portion in the flow aperture may be controlled.Type: ApplicationFiled: July 29, 2014Publication date: February 5, 2015Inventors: David Kirk Conn, Christopher Paul Reed, Andrew J. Parry, Alain P. Dorel, Staffan Eriksson, Jonathan James, Stuart Alan Kolbe
-
Patent number: 8501419Abstract: Novel thymidine kinase (TK1) derived peptide consisting of the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2 is employed to obtain ligands having specificity to the peptide. The ligand may be an antibody or fragment thereof and may be used in various methods and kits for health screening and the like.Type: GrantFiled: May 23, 2008Date of Patent: August 6, 2013Assignee: Arocell ABInventor: Staffan Eriksson
-
Publication number: 20100311081Abstract: A method of predicting the likelihood of cancer relapse in a patient undergoing treatment for cancer is provided. The binding response level of an immunoreactive material (IM) comprising thymidine kinase 1 (TK1) protein is determined in a body fluid sample of a patient and the likelihood of relapse of the cancer disease is predicted based on this determined IM binding response level. Those patients that run a risk of cancer progress and relapse 1-15 years after the cancer treatment may be identified directly by the IM binding response level within a few months following initiation of the treatment.Type: ApplicationFiled: November 27, 2009Publication date: December 9, 2010Applicant: AROCELL ABInventors: Sven SKOG, Staffan ERIKSSON, Bernhard TRIBUKAIT, Qimin HE
-
Publication number: 20100173329Abstract: Novel thymidine kinase (TK1) derived peptide consisting of the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2 is employed to obtain ligands having specificity to the peptide. The ligand may be an antibody or fragment thereof and may be used in various methods and kits for health screening and the like.Type: ApplicationFiled: May 23, 2008Publication date: July 8, 2010Inventor: Staffan Eriksson
-
Publication number: 20090052278Abstract: A technique includes generating one or more sweep sequences for one or more seismic vibrators for a seismic survey and evaluating a cost for the sequence(s). The technique includes perturbing the sequence(s) and continuing the evaluation and perturbing until the cost is within a limit or a maximum number of perturbations is reached.Type: ApplicationFiled: July 16, 2008Publication date: February 26, 2009Inventors: Kambiz Iranpour, Staffan Eriksson, Christer Hoerlin
-
Publication number: 20070141650Abstract: The present invention involves early prediction of progression of a cancer disease in patients treated for cancer. According to the invention the binding response level of an immunoreactive material (IM) comprising thymidine kinase 1 (TK1) protein is determined in a body fluid sample of a patient and the likelihood of progress of the cancer disease is estimated based directly on this determined IM binding response level. Those patients that run a risk of cancer progress and tumor relapse 1-15 years after the cancer treatment may be identified directly by the IM binding response level according to the invention within a few months following initiation of the treatment.Type: ApplicationFiled: May 14, 2004Publication date: June 21, 2007Inventors: Sven Skog, Staffan Eriksson, Bernhard Tribukait, Qimin He
-
Publication number: 20060035295Abstract: The present invention concerns a new method that enables safe, rapid, accurate and specific determination of thymidine kinase 1 activity in human or animal body fluids and tissue/cell extracts for routine analysis of samples with low levels of activity by using AZT or 3? derivatives of thymidine as substrate and determining the phosphorylated products formed in the reaction with thymidine kinase 1 activity. The invention further relates to the use of said method for the diagnosis, monitoring and prognostics of diseases such as cancer.Type: ApplicationFiled: July 11, 2003Publication date: February 16, 2006Inventors: Anders Oehrvik, Staffan Eriksson
-
Patent number: 6282918Abstract: In an absorption refrigerating apparatus (18) the pump pipe (42) is made of a material, which is more corrosion resistant to the working medium than the material of the rest of the apparatus. In order to prevent galvanic corrosion in the boiler the pump pipe (42) can be electrically insulated (72, 74) from the rest of the boiler.Type: GrantFiled: January 21, 2000Date of Patent: September 4, 2001Assignee: Aktiebolaget ElectroluxInventors: Per Levin, Staffan Eriksson, Carl Lindhagen